If you liked this article you might like

Biogen Spine Disease Drug Sales Strong in First Quarter Since Commercial Launch
Biogen Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boost Sales
Biomarin Rare Disease Drug Picks Up European Endorsement Ahead of FDA Action
TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market